Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + anlotinib + taxane chemotherapy in immunotherapy-pretreated recurrent/metastatic nasopharyngeal carcinoma
ChiCTR2600135539Phase 2Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in nasopharyngeal carcinoma (NPC), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Objective response rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600135539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135539.